Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial-Reference-Cited by-同舟云学术

Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial

Published:2017-06 Issue:6 Volume:18 Page:755-769
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Earl Helena M,Hiller Louise,Howard Helen C,Dunn Janet A,Young Jennie,Bowden Sarah J,McDermaid Michelle,Waterhouse Anna K,Wilson Gregory,Agrawal Rajiv,O'Reilly Susan,Bowman Angela,Ritchie Diana M,Goodman Andrew,Hickish Tamas,McAdam Karen,Cameron David,Dodwell David,Rea Daniel W,Caldas Carlos,Provenzano Elena,Abraham Jean E,Canney Peter,Crown John P,Kennedy M John,Coleman Robert,Leonard Robert C,Carmichael James A,Wardley Andrew M,Poole Christopher J

Publisher

Elsevier BV

Subject

Oncology

Reference32 articles.

1. Polychemotherapy for early breast cancer: an overview of the randomised trials;Lancet,1998

2. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer;Poole;N Engl J Med,2006

3. Randomized Trial Comparing Cyclophosphamide, Epirubicin, and Fluorouracil With Cyclophosphamide, Methotrexate, and Fluorouracil in Premenopausal Women With Node-Positive Breast Cancer: Update of National Cancer Institute of Canada Clinical Trials Group Trial MA5

4. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group.

5. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer;Henderson;J Clin Oncol,2003

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting cancer-specific metabolic pathways for developing novel cancer therapeutics;Frontiers in Immunology;2022-12-22

2. Reporting of tobacco use and tobacco-related analyses in cancer cooperative group clinical trials: a systematic scoping review;ESMO Open;2022-12

3. Apoferritin-Encapsulated Jerantinine A for Transferrin Receptor Targeting and Enhanced Selectivity in Breast Cancer Therapy;ACS Omega;2022-06-13

4. Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy;Journal of Hematology & Oncology;2022-04-27

5. Engineering of small-molecule lipidic prodrugs as novel nanomedicines for enhanced drug delivery;Journal of Nanobiotechnology;2022-01-24